RTTNews BiotechDoubao · 实盘不做把握 6/10不做原因:已被定价
北京时间·🕒 发布 11:23:10·⟳ 抓取 11:30:15 +7m05s·⚡ 决策 10-09 11:32:21 +2m06s·18.2 天前
信达生物信必敏®（替妥尤单抗N01）非活动性甲状腺眼病III期RESTORE-3达到主要终点
首发为公司PR Newswire通稿（10-09 08:00 HKT，港股开盘前），RTTNews仅为约3.5小时后的二手转述；港股上午盘已充分交易，当前90.7港元、当日-2.05%，延续昨日-5%跌势，市场未给予正反馈，且适应症扩展仍需sNDA审批、短期无业绩增量，剩余正edge不足。
📄 原文RTTNews Biotech↗ 原文
Innovent's Phase 3 Success Expands SYCUME's Potential In Thyroid Eye Disease
Business Business Latest Headlines Top Stories Breaking News Earnings Biotech Investors Stock Alerts IPOs M&A Canadian…
不做 信达生物制药（01801.HK）
催化为港股开盘前的官方明牌通稿，上午盘已充分交易且股价不涨反跌约2%，短线edge已被消化；适应症扩展仍需sNDA审批、短期无业绩增量，风险回报不支持追多。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
信必敏非活动期TED III期成功，临床与长期市场空间逻辑正面；但官方通稿在港股开盘前已发布，上午盘消化后股价下跌，短线催化已被定价且兑现遥远，不具可交易edge，回避。
消息传播链
- 公司在港股开盘前90分钟发布RESTORE-3达主要终点的官方通稿（应答率60.4%、降低1.88mm），为本次催化首发锚点。市场反应:港股09:30开盘后整个上午时段交易该消息，至11:28报90.7港元、当日-2.05%，未现正向重定价。
- RTTNews在官方通稿约3.5小时后刊发转述报道，文中称1801.HK报90.35、跌2.43%，属滞后二手源，非首发。
关键理由
- RESTORE-3阳性把信必敏证据链扩展到占患者比例可观的非活动期TED，长期有望拓宽适应症与用药人群。
- 但该药物在公司百亿级收入盘子中占比小，本次仅为topline读出、尚需补充申请获批，短期不产生业绩增量。
主要风险
- 扩展适应症的sNDA提交与批准时点、完整数据（含安全性细节）仍存在不确定性。
- 港股早盘对该明确利好以下跌回应，显示市场情绪偏弱或资金借消息出货，追多易承接抛压。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-09 · 影响 weakens
股价昨日-5.03%、今日早盘续跌约2%，市场对该利好无正反馈；信必敏相对公司百亿级产品收入占比小，削弱做多edge。
检索:信达生物 信必敏 teprotumumab 销售占比 近期利空 股价 下跌 2026年10月 原文 ↗ - 做多前查反向 · 来源 kb_search · 影响 none
kb_search服务连接被拒（Connection refused），未取得内部库关于该药销售峰值/患者池的量化数据，无法坐实短期业绩弹性。
检索:信达生物 替妥木单抗 甲状腺眼病 销售峰值 市场规模
先例如何影响了这次决策
对本次决策的影响:先例不足叠加早盘负反馈，支持回避而非做多；未凭薄弱样本编造幅度。
方向:未取得可锚定首发时点、同市场同相位的对齐先例；检索仅见信达IBI363 ASCO数据大涨（不同机制/事件类型）等背景信息，不足以校准本次读出的幅度。
涨幅量级:缺乏高相似、锚干净的港股同类III期读出先例，无法据以设定tp/sl；而标的实时市场反应（早盘下跌）本身已是更直接的定价证据。
形态:无足够样本判断见光死模式，但本次利好早盘以下跌回应，与'明牌临床利好缺乏短线edge'的方向一致。
工具执行结果 · 成功 6 · 降级 0 · 失败 1 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 16 ms
{"result": "search_processed_events:agent query=`1801.hk teprotumumab n01 proptosis 60.4% week 24 | innovent 信达生物 sycume teprotumumab restore-3 phase 3 inactive thyroid eye disease | 替妥木单抗 非活动性甲状腺相关眼病 iii期 临床 主要终点`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候 - stock_quote 成功 stock_tools HTTP · 84 ms
{ - fetch_decision_experience 成功 stock_tools_inprocess · 2 ms
{ - kb_search 失败 stock_tools HTTP · 56 ms
kb_search 服务暂不可用；这不是一条知识库命中。 - web_search 成功 doubao_search · 1,606 ms
豆包搜索结果（原始查询:信达生物 替妥木单抗 RESTORE-3 非活动性甲状腺相关眼病 III期 达到主要终点 公告；API SearchType:web） - web_search 成功 doubao_search · 1,833 ms
豆包搜索结果（原始查询:Innovent SYCUME teprotumumab RESTORE-3 inactive thyroid eye disease phase 3 primary endpoint；API SearchType:web） - web_search 成功 doubao_search · 1,506 ms
豆包搜索结果（原始查询:信达生物 01801 III期临床 达到主要终点 公告后 股价 涨 反应 历史 IBI363 玛仕度肽；API SearchType:web）
原文全文
展开原文 · 9,335 字
Innovent's Phase 3 Success Expands SYCUME's Potential In Thyroid Eye Disease
Business
Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
Industry News
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Cryptocurrency
Crypto
Cryptocurrency
Blockchain
Markets
Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
Politics
US
World
White House
Elections
General News
Forex
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard
Health
Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Entertainment
Top Stories
Music news
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium Services
Premium
Intelligent Investor
Biotech Investor
NEW
Login
More
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Biotech Daily Dose
Innovent's Phase 3 Success Expands SYCUME's Potential In Thyroid Eye Disease
By
TajSabreen Ahamed
✉
Published:
10/8/2026 11:23 PM ET
Follow Us
Join Us
Add
as your preferred news source on Google
Add Now
Innovent Biologics announced that its Phase 3 RESTORE-3 study of SYCUME (teprotumumab N01 injection) met the primary endpoint in Chinese patients with inactive thyroid eye disease (TED), marking another clinical milestone for the therapy.
The study showed that SYCUME significantly reduced eye protrusion, a hallmark symptom of the disease, while maintaining a favorable safety profile.
Thyroid eye disease is an autoimmune condition that can cause eye bulging, double vision, discomfort, and vision impairment. While inflammation is more active in the early stages of the disease, many patients continue to experience long-term symptoms even after the inflammatory phase subsides.
The RESTORE-3 trial was a randomized, double-blind, placebo-controlled Phase 3 study involving 116 patients with inactive TED. Participants were assigned to receive either SYCUME or placebo, with the primary endpoint measuring the proportion of patients achieving a meaningful reduction in eye protrusion at Week 24.
According to the company, SYCUME achieved a 60.4% proptosis response rate and produced a least-squares mean reduction of 1.88 mm from baseline in eye protrusion, meeting both the primary and key secondary efficacy endpoints.
SYCUME is a recombinant antibody that targets the insulin-like growth factor-1 receptor (IGF-1R), a pathway believed to play a central role in TED. The therapy is already approved in China and was added to the country's National Reimbursement Drug List in January 2026, improving patient access.
The positive RESTORE-3 results extend the clinical evidence supporting SYCUME across different stages of thyroid eye disease and may help broaden treatment options for patients with inactive TED, a population that represents a substantial portion of those living with the condition.
1801.HK has traded between HKD 69.55 and HKD 112.70 over the past year. The stock is currently trading at HKD 90.35, down 2.43%.
For comments and feedback contact: editorial@rttnews.com
Business News
Slide Shows
Biotech Stocks Facing FDA Decision In October 2026
Biotech Stocks Facing FDA Decision In September 2026
Biotech Stocks Facing FDA Decision In August 2026
Latest Updates on Middle East War
U.S. Stocks Close Mostly Lower On Spike In Oil Prices, OpenAI Revenue Concerns
October 08, 2026 16:17 ET
U.S. Stocks Mostly Lower As Crude Oil Prices Spike
October 08, 2026 11:19 ET
Renewed Spike In Crude Oil Prices May Weigh On Wall Street
October 08, 2026 08:50 ET
U.S. Stocks Giving Back Ground Following Recent Strength
October 07, 2026 11:01 ET
Profit Taking May Contribute To Initial Pullback On Wall Street
October 07, 2026 08:57 ET
View More
October 2026 FDA Decisions: 4 Key Drug Approvals Biotech Investors Should Watch
September 28, 2026 06:25 ET
Every month, the FDA issues decisions on drug approvals — and for biotech investors, these dates are important milestones for the companies and patients involved. In this video, we highlight five key FDA decisions scheduled for October 2026, covering potential approvals and expanded indications across oncology, rare diseases, ophthalmology, and chronic hepatitis B.
View More Videos
RELATED NEWS
Innovent Reports Updated Phase 1 Data For IBI3003 In Relapsed/Refractory Multiple Myeloma
Innovent's Jaypirca Gets Expanded NMPA Approval For CLL/SLL
Innovent Expands Phase 3 IBI363 Study To Non-Squamous Lung Cancer; Stock Down
Altruist Biologics' Suzhou Facility Clears EMA GMP Inspection
Innovent Announces 2026 Interim Results And Strategic Vision Toward 2030
Latest Updates on COVID-19
View More
Editor's Pick
Most Read
Most Emailed
American Airlines To Expand Starlink Connectivity To More Than 1000 Mainline Aircraft
October 08, 2026 11:57 ET
No Evidence Siberia Lab Worker Died Of Plague, Russia Tells WHO
October 08, 2026 10:10 ET
Canadian Author Anne Carson Wins Nobel Prize In Literature
October 08, 2026 09:42 ET
U.S. Jobless Claims Unexpectedly Dip From Upwardly Revised Level
October 08, 2026 09:16 ET
Nearly 70 Million Children Now Have A Trump Account: White House
October 08, 2026 08:27 ET
PepsiCo Q3 Profit Climbs, Core Margin Down; Updates FY26 View; Stock Gains
October 08, 2026 08:12 ET
ISIS-inspired Teenager Who Plotted Mass-Shooting At Mall Of America Arrested
October 08, 2026 07:39 ET
British Consulate In East Jerusalem Not Closing, But Renamed As UK Mission
October 08, 2026 07:21 ET
Istanbul Overtakes London Heathrow As World's Most-connected Airport
October 08, 2026 07:00 ET
Tesco Plc Stock Gains On H1 Profit Growth, FY27 Outlook Upgrade, Addl. Buyback
October 08, 2026 05:39 ET
Fed Minutes Reveal Officials Expect Another Rate Hike This Year
October 07, 2026 14:23 ET
RBI Shifts To 'Calibrated Tightening' As Rate-Hiking Cycle Begins
October 07, 2026 12:14 ET
Applied Digital Secures Access To 1 GW Power Capacity In Finland
October 06, 2026 15:07 ET
AkzoNobel To Sell Southeast Asia Decorative Paints Business To Nippon Paint In $1.35 Bln Deal
October 04, 2026 21:49 ET
Google's Fitbit Edge Tracker May Cost Around $180 With 7-Day Battery Life
October 06, 2026 18:17 ET
CD&R And McKesson To Acquire Option Care Health
October 06, 2026 08:23 ET
Emera, Canadian Utilities To Merge In C$72 Bln Deal
October 06, 2026 07:23 ET
Constellation Acquires SpikeAde For $75 Mln; Shares Down
October 06, 2026 17:22 ET
Fairfax Financial To Partner With Wittington To Acquire Boots Group
October 07, 2026 09:49 ET
IRhythm Begins Notifying Patients Following Review Of Cybersecurity Incident
October 04, 2026 03:07 ET
Crescent Energy To Buy Devon's Eagle Ford Assets For $3.85 Bln; Launches $1 Bln Stock Offering
October 08, 2026 07:53 ET
PepsiCo Recalls Gatorade In 37 States Over Undeclared Dyes
October 05, 2026 18:04 ET
PepsiCo Q3 Profit Climbs, Core Margin Down; Updates FY26 View; Stock Gains
October 08, 2026 08:12 ET
Nexus Advanced Technologies Signs Exclusivity For $500 Mln Defense Tech Reverse Merger
October 06, 2026 08:31 ET
Bayer To Invest $2.2 Bln In Ohio Pharma Manufacturing Campus
October 03, 2026 10:21 ET
Novo Nordisk Plans Denecimib U.S. Launch In H1 2027 Amid FDA Review Extension
October 03, 2026 09:12 ET
IRhythm Begins Notifying Patients Following Review Of Cybersecurity Incident
October 04, 2026 03:07 ET
FDA Approves Expanded Use Of Lilly's Jaypirca For CLL/SLL
October 03, 2026 10:42 ET
CSL, Alentis Therapeutics Partner On Lixudebart In Deal Worth Up To $1.6 Bln
October 04, 2026 21:10 ET
Bayer To Invest $2.2 Bln In Ohio Pharma Site, To Create 2,100 Jobs
October 03, 2026 11:03 ET
AkzoNobel To Sell Southeast Asia Decorative Paints Business To Nippon Paint In $1.35 Bln Deal
October 04, 2026 21:49 ET
Genmab Reports Positive Phase 1/2 Data For Rina-S In Resistant Ovarian Cancer
October 04, 2026 01:40 ET
Kaneko Seeds Co Ltd Reports Rise In Q1 Bottom Line
October 05, 2026 00:33 ET
FAA Reportedly Finds Boeing 737 Max Software Issue Poses No Safety Risk
October 04, 2026 10:53 ET
Skanska Enters Contract For New High School Project In Renton
October 05, 2026 02:05 ET
Oracle Invests $10 Mln To Support Nashville Symphony's Recovery And Restore Operations
October 04, 2026 20:44 ET
Editors Pick
PepsiCo Q3 Profit Climbs, Core Margin Down; Updates FY26 View; Stock Gains
October 08, 2026 08:12 ET
Tesco Plc Stock Gains On H1 Profit Growth, FY27 Outlook Upgrade, Addl. Buyback
October 08, 2026 05:39 ET
Walmart Recalls Over 4.4 Mln Grill Brushes For Ingestion Risk
October 02, 2026 09:11 ET
Gias Foods Recalls Bettergoods Pasta Sold At Walmart Over Listeria Risk
October 02, 2026 08:47 ET
Loading...
Business
Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
Industry News
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Cryptocurrency
Crypto
Cryptocurrency
Blockchain
Markets
Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
Politics
US
World
White House
Elections
General News
Forex
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard
Health
Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Entertainment
Top Stories
Music news
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium Services
Premium
Intelligent Investor
Biotech Investor
NEW
Login
More
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Biotech Daily Dose
Innovent's Phase 3 Success Expands SYCUME's Potential In Thyroid Eye Disease
By
TajSabreen Ahamed
✉
Published:
10/8/2026 11:23 PM ET
Follow Us
Join Us
Add
as your preferred news source on Google
Add Now
Innovent Biologics announced that its Phase 3 RESTORE-3 study of SYCUME (teprotumumab N01 injection) met the primary endpoint in Chinese patients with inactive thyroid eye disease (TED), marking another clinical milestone for the therapy.
The study showed that SYCUME significantly reduced eye protrusion, a hallmark symptom of the disease, while maintaining a favorable safety profile.
Thyroid eye disease is an autoimmune condition that can cause eye bulging, double vision, discomfort, and vision impairment. While inflammation is more active in the early stages of the disease, many patients continue to experience long-term symptoms even after the inflammatory phase subsides.
The RESTORE-3 trial was a randomized, double-blind, placebo-controlled Phase 3 study involving 116 patients with inactive TED. Participants were assigned to receive either SYCUME or placebo, with the primary endpoint measuring the proportion of patients achieving a meaningful reduction in eye protrusion at Week 24.
According to the company, SYCUME achieved a 60.4% proptosis response rate and produced a least-squares mean reduction of 1.88 mm from baseline in eye protrusion, meeting both the primary and key secondary efficacy endpoints.
SYCUME is a recombinant antibody that targets the insulin-like growth factor-1 receptor (IGF-1R), a pathway believed to play a central role in TED. The therapy is already approved in China and was added to the country's National Reimbursement Drug List in January 2026, improving patient access.
The positive RESTORE-3 results extend the clinical evidence supporting SYCUME across different stages of thyroid eye disease and may help broaden treatment options for patients with inactive TED, a population that represents a substantial portion of those living with the condition.
1801.HK has traded between HKD 69.55 and HKD 112.70 over the past year. The stock is currently trading at HKD 90.35, down 2.43%.
For comments and feedback contact: editorial@rttnews.com
Business News
Slide Shows
Biotech Stocks Facing FDA Decision In October 2026
Biotech Stocks Facing FDA Decision In September 2026
Biotech Stocks Facing FDA Decision In August 2026
Latest Updates on Middle East War
U.S. Stocks Close Mostly Lower On Spike In Oil Prices, OpenAI Revenue Concerns
October 08, 2026 16:17 ET
U.S. Stocks Mostly Lower As Crude Oil Prices Spike
October 08, 2026 11:19 ET
Renewed Spike In Crude Oil Prices May Weigh On Wall Street
October 08, 2026 08:50 ET
U.S. Stocks Giving Back Ground Following Recent Strength
October 07, 2026 11:01 ET
Profit Taking May Contribute To Initial Pullback On Wall Street
October 07, 2026 08:57 ET
View More
October 2026 FDA Decisions: 4 Key Drug Approvals Biotech Investors Should Watch
September 28, 2026 06:25 ET
Every month, the FDA issues decisions on drug approvals — and for biotech investors, these dates are important milestones for the companies and patients involved. In this video, we highlight five key FDA decisions scheduled for October 2026, covering potential approvals and expanded indications across oncology, rare diseases, ophthalmology, and chronic hepatitis B.
View More Videos
RELATED NEWS
Innovent Reports Updated Phase 1 Data For IBI3003 In Relapsed/Refractory Multiple Myeloma
Innovent's Jaypirca Gets Expanded NMPA Approval For CLL/SLL
Innovent Expands Phase 3 IBI363 Study To Non-Squamous Lung Cancer; Stock Down
Altruist Biologics' Suzhou Facility Clears EMA GMP Inspection
Innovent Announces 2026 Interim Results And Strategic Vision Toward 2030
Latest Updates on COVID-19
View More
Editor's Pick
Most Read
Most Emailed
American Airlines To Expand Starlink Connectivity To More Than 1000 Mainline Aircraft
October 08, 2026 11:57 ET
No Evidence Siberia Lab Worker Died Of Plague, Russia Tells WHO
October 08, 2026 10:10 ET
Canadian Author Anne Carson Wins Nobel Prize In Literature
October 08, 2026 09:42 ET
U.S. Jobless Claims Unexpectedly Dip From Upwardly Revised Level
October 08, 2026 09:16 ET
Nearly 70 Million Children Now Have A Trump Account: White House
October 08, 2026 08:27 ET
PepsiCo Q3 Profit Climbs, Core Margin Down; Updates FY26 View; Stock Gains
October 08, 2026 08:12 ET
ISIS-inspired Teenager Who Plotted Mass-Shooting At Mall Of America Arrested
October 08, 2026 07:39 ET
British Consulate In East Jerusalem Not Closing, But Renamed As UK Mission
October 08, 2026 07:21 ET
Istanbul Overtakes London Heathrow As World's Most-connected Airport
October 08, 2026 07:00 ET
Tesco Plc Stock Gains On H1 Profit Growth, FY27 Outlook Upgrade, Addl. Buyback
October 08, 2026 05:39 ET
Fed Minutes Reveal Officials Expect Another Rate Hike This Year
October 07, 2026 14:23 ET
RBI Shifts To 'Calibrated Tightening' As Rate-Hiking Cycle Begins
October 07, 2026 12:14 ET
Applied Digital Secures Access To 1 GW Power Capacity In Finland
October 06, 2026 15:07 ET
AkzoNobel To Sell Southeast Asia Decorative Paints Business To Nippon Paint In $1.35 Bln Deal
October 04, 2026 21:49 ET
Google's Fitbit Edge Tracker May Cost Around $180 With 7-Day Battery Life
October 06, 2026 18:17 ET
CD&R And McKesson To Acquire Option Care Health
October 06, 2026 08:23 ET
Emera, Canadian Utilities To Merge In C$72 Bln Deal
October 06, 2026 07:23 ET
Constellation Acquires SpikeAde For $75 Mln; Shares Down
October 06, 2026 17:22 ET
Fairfax Financial To Partner With Wittington To Acquire Boots Group
October 07, 2026 09:49 ET
IRhythm Begins Notifying Patients Following Review Of Cybersecurity Incident
October 04, 2026 03:07 ET
Crescent Energy To Buy Devon's Eagle Ford Assets For $3.85 Bln; Launches $1 Bln Stock Offering
October 08, 2026 07:53 ET
PepsiCo Recalls Gatorade In 37 States Over Undeclared Dyes
October 05, 2026 18:04 ET
PepsiCo Q3 Profit Climbs, Core Margin Down; Updates FY26 View; Stock Gains
October 08, 2026 08:12 ET
Nexus Advanced Technologies Signs Exclusivity For $500 Mln Defense Tech Reverse Merger
October 06, 2026 08:31 ET
Bayer To Invest $2.2 Bln In Ohio Pharma Manufacturing Campus
October 03, 2026 10:21 ET
Novo Nordisk Plans Denecimib U.S. Launch In H1 2027 Amid FDA Review Extension
October 03, 2026 09:12 ET
IRhythm Begins Notifying Patients Following Review Of Cybersecurity Incident
October 04, 2026 03:07 ET
FDA Approves Expanded Use Of Lilly's Jaypirca For CLL/SLL
October 03, 2026 10:42 ET
CSL, Alentis Therapeutics Partner On Lixudebart In Deal Worth Up To $1.6 Bln
October 04, 2026 21:10 ET
Bayer To Invest $2.2 Bln In Ohio Pharma Site, To Create 2,100 Jobs
October 03, 2026 11:03 ET
AkzoNobel To Sell Southeast Asia Decorative Paints Business To Nippon Paint In $1.35 Bln Deal
October 04, 2026 21:49 ET
Genmab Reports Positive Phase 1/2 Data For Rina-S In Resistant Ovarian Cancer
October 04, 2026 01:40 ET
Kaneko Seeds Co Ltd Reports Rise In Q1 Bottom Line
October 05, 2026 00:33 ET
FAA Reportedly Finds Boeing 737 Max Software Issue Poses No Safety Risk
October 04, 2026 10:53 ET
Skanska Enters Contract For New High School Project In Renton
October 05, 2026 02:05 ET
Oracle Invests $10 Mln To Support Nashville Symphony's Recovery And Restore Operations
October 04, 2026 20:44 ET
Editors Pick
PepsiCo Q3 Profit Climbs, Core Margin Down; Updates FY26 View; Stock Gains
October 08, 2026 08:12 ET
Tesco Plc Stock Gains On H1 Profit Growth, FY27 Outlook Upgrade, Addl. Buyback
October 08, 2026 05:39 ET
Walmart Recalls Over 4.4 Mln Grill Brushes For Ingestion Risk
October 02, 2026 09:11 ET
Gias Foods Recalls Bettergoods Pasta Sold At Walmart Over Listeria Risk
October 02, 2026 08:47 ET
Loading...
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
bc289d3c3a· 2026-10-09 11:32 · doubao / doubao-seed-evolving-latest-version · 策略包d5018cb8913f当前